![]() |
![]() |
![]() |
![]() |
PO-004 | Texture analysis using computed tomography data may be helpful for the risk stratification of clinical significant portal hypertension in patients with liver cirrhosis | Shang Wan | ![]() |
![]() |
|||
PO-005 | Quantitative parameters of esophageal varices based on computed tomography may be used for predicting severe varices in patients with liver cirrhosis | Shang Wan | ![]() |
![]() |
|||
PH-017 | Mixed HCC-CCA originates from hepatic progenitor cells, is dependent on IL6 signaling and is ablated by senolytic agents | nofar rosenberg | ![]() |
![]() |
|||
PO-022 | Hepatocellular carcinoma is associated with an increased prevalence of metabolic syndrome after liver transplantation | Asahi Hoque | ![]() |
![]() |
|||
PO-024 | Occult hepatitis B virus infection and hepatocellular carcinoma occurrence after hepatitis C virus eradication: the silent enemy | Cristina Muzica | ![]() |
![]() |
|||
PH-025 | A new 3D Slicer plug-in for the interactive annotation and segmentation of liver anatomy | Antoine Vacavant | ![]() |
![]() |
|||
PO-028 | Mathematical modeling of cancer cells and vasculature dynamics with serological and imaging biomarkers suggests synergistic effects of TACE and TKIs in HCC patients | Francesco Damone | ![]() |
![]() |
|||
PH-029 | Independent validation of a glycomics-based test associated with risk of HCC development in cirrhosis: a new tool for screening optimisation? | Verhelst Xavier | ![]() |
![]() |
|||
PH-030 | Pretransplant changes in serum protein glycosylation are associated to risk of HCC recurrence after liver transplantation and provide a potential prognostic biomarker: a proof-of-concept study | Verhelst Xavier | ![]() |
![]() |
|||
PH-038 | Circulating tumor DNA methylation markers for diagnosis of liver cancer: A multicenter diagnostic trial | Maomao Cao | ![]() |
![]() |
|||
PO-047 | The clinical experience with stereotactic ablative radiotherapy for hepatocellular carcinoma in a tertiary referral center: a case series | Sjoerd Spijkerboer | ![]() |
![]() |
|||
PH-058 | The systemic inflammatory response identifies patients with adverse clinical outcome from immunotherapy in hepatocellular carcinoma. | Claudia Fulgenzi | ![]() |
![]() |
|||
PO-064 | Gut bacteria modulate anti-tumour immunity in patients with Hepatocellular Carcinoma | Dhruti Devshi | ![]() |
![]() |
|||
PO-068 | Hepatocellular carcinoma alters granulopoiesis to produce neutrophils with an immature phenotype | Daniel Geh | ![]() |
![]() |
|||
PH-073 | Tumor intrinsic and extrinsic role of Axl in models of hepatocellular carcinoma | Kristina Breitenecker | ![]() |
![]() |
|||
PH-076 | Transarterial chemoembolization for hepatocellular carcinoma in clinical practice: temporal trends and survival outcomes over the last three decades in Italy | Filippo Pelizzaro | ![]() |
![]() |
|||
BP-094 | PRAME is a novel target of Axl signaling in hepatocellular carcinoma progression | Viola Hedrich | ![]() |
![]() |
|||
PH-098 | Effect of liver stiffness on hepatocellular carcinoma phenotype in a biomimetic 3D model | Jaafar Khaled | ![]() |
![]() |
|||
PO-102 | Inhibiting IRE1-a endonuclease activity potentiates the effect of doxorubicin in hepatocellular carcinoma. | MARIA KOPSIDA | ![]() |
![]() |
|||
PO-107 | Ouctome of hydrodissection radiofrequency ablation in patients with pericholecystic hepatocellular carcinoma | Benedetta Stefanini | ![]() |
![]() |
|||
PO-119 | Efficacy of combination therapy with lenvatinib, programmed cell death 1 inhibitors and transarterial therapy: a propensity score-matching cohort study | Wei Lu | ![]() |
![]() |
|||
BP-120 | Hepatocellular carcinoma tumor burden in the GAN diet-induced obese mouse model of NASH with advanced fibrosis | Michael Feigh | ![]() |
![]() |
|||
BP-122 | Unrecognized liver cirrhosis: common and associated with worse survival in patients diagnosed with hepatocellular carcinoma a Swedish nationwide cohort study | Juan Vaz | ![]() |
![]() |
|||
PO-126 | Novel platinum-based chemotherapeutic agents halt cholangiocarcinoma progression through the induction of inter-strand DNA breaks, preventing DNA repair mechanisms | Irene Olaizola | ![]() |
![]() |
|||
PH-127 | Fatty acid oxidation fuels the progression of highly proliferative cholangiocarcinoma cells | Mikel Ruiz de Gauna | ![]() |
![]() |
|||
PH-128 | Progression patterns and therapeutic sequencing following immune checkpoint inhibition for HCC: an observational study. | David J Pinato | ![]() |
![]() |
|||
PO-129 | Clinicopathological and survival features of hepatic lymphomas: a retrospective single-center study | Emanuel Dias | ![]() |
![]() |
|||
PO-132 | Enhanced recovery after surgery: application of 2016 liver surgery guidelines in a middle volume western center | Alessandro Fogliati | ![]() |
![]() |
|||
PO-135 | Prominent pseudoacini in focal nodular hyperplasia: a potential diagnostic pitfall | Donghai Wang | ![]() |
![]() |
|||
PO-141 | Investigating CXCR2 inhibition anti-PD1 immunotherapy in a NASH-HCC mouse model using Imaging Mass Cytometry | Erik Ramon Gil | ![]() |
![]() |
|||
PO-143 | Hepatocellular carcinoma recurrence post Liver transplant | Yaqza Hussain | ![]() |
![]() |
|||
PO-148 | Systemic treatments with tyrosine kinase inhibitors and platinum-based chemotherapy in patients with unresectable or metastatic hepato-cholangiocarcinoma | Elia Gigante | ![]() |
![]() |
|||
PO-150 | Involvement of E2F2-miR34a-5p axis in the metabolic dysregulation of MAFLD-related HCC | Maider Apodaka Biguri | ![]() |
![]() |
|||
PO-154 | Association between metabolic disorders and biliary tract cancer: impact of an emergent risk factor in a real-world cohort. | Leonardo da Fonseca | ![]() |
![]() |
|||
PO-159 | Epidemiology of hepatocellular carcinoma in Portugal | Mario Jorge Silva | ![]() |
![]() |
|||
PO-160 | CXCR2 inhibition sensitises to anti-PD1 therapy in NASH-HCC | jack leslie | ![]() |
![]() |
|||
PH-161 | Opposite roles for PD-1 expressing tissue resident and exhausted T cells in Hepatocellular Carcinoma | Maryam Barsch | ![]() |
![]() |
|||
PO-163 | The NADPH oxidase NOX4 regulates redox and metabolic homeostasis in hepatocellular carcinoma | Irene Peñuelas | ![]() |
![]() |
|||
PO-170 | P53 and VEGF immunoexpression are predictive biomarkers of Sorafenib efficacy in an experimental model of NASH-related HCC | João Pedro Nassar Reis | ![]() |
![]() |
|||
PO-175 | A retrospective real-world study of transarterial gemcitabine-based chemoembolization plus lenvatinib with or without a PD-1 inhibitor for unresectable intrahepatic cholangiocarcinoma | ya li | ![]() |
![]() |
|||
PO-176 | Factors associated with the radiological response of atezolizumab plus bevacizumab for unresectable hepatocellular carcinoma | Yuka Hayakawa | ![]() |
![]() |
|||
PH-177 | Cholangiocarcinoma-on-chip: a 3D liver tumor model | michela polidoro | ![]() |
![]() |
|||
PO-179 | Altered glutamine metabolism in intrahepatic cholangiocarcinoma: biological effects of glutaminase inhibitor | michela polidoro | ![]() |
![]() |
|||
PH-181 | The development of ex vivo human models of hepatocellular carcinoma in precision cut liver slices for high throughput screening of anti-cancer therapies | Amy Collins | ![]() |
![]() |
|||
PO-190 | Role of ABC drug efflux pumps in the resistance of hepatoblastoma to conventional chemotherapy | Candela Cives-Losada | ![]() |
![]() |
|||
PO-193 | MiR-30e-3p plays a dual role in hepatocellular carcinoma and predicts sorafenib resistance | Ilaria Leoni | ![]() |
![]() |
|||
PH-195 | Usefulness of serum metabolomic profiling for the differential diagnosis in liver cancer: a validation study | Rocio IR Macias | ![]() |
![]() |
|||
PO-202 | Direct and indirect antitumoral effects of cold atmospheric plasma : a disruptive technological approach for the local treatment of cholangiocarcinoma | Allan Pavy | ![]() |
![]() |
|||
PO-203 | The probability to be cured after surgery for hepatocellular carcinoma: can these patients reach again the general population life span? A national multicentric epidemiologic study | Simone Famularo | ![]() |
![]() |
|||
PO-211 | Stratification of cirrhosis etiologies identifies novel immune biomarkers for early stage hepatocellular carcinoma | Boris Beudeker | ![]() |
![]() |
|||
PO-221 | Liver biopsy biomarkers in a phase 1 study of the prodrug MIV-818 demonstrates proof-of-concept for cancer in the liver | Fredrik Oberg | ![]() |
![]() |
|||
PO-224 | Notch signalling is significantly altered in KPPTom mice, a bespoke murine model of intrahepatic cholangiocarcinoma | Anabel Martinez Lyons | ![]() |
![]() |
|||
PO-225 | BH3 mimetics for precision prevention for beta-catenin mutant hepatocellular carcinoma | Stephanie May | ![]() |
![]() |
|||
PO-231 | Early Kupffer cell depletion does not affect hepatocellular carcinoma progression in mice | Bart Vanderborght | ![]() |
![]() |
|||
PO-235 | Disease positioning identifies distinct hepatocellular carcinoma subtypes within genetically engineered mouse models which transcriptionally relate to equivalent subclasses in human hepatocellular carcinoma | Miryam Mller | ![]() |
![]() |
|||
PH-241 | ZEB1 expression mediates chemoresistance in cholangiocarcinoma by disrupting the pro/anti-apoptotic balance in stromal myofibroblasts | Javier Vaquero | ![]() |
![]() |
|||
PO-259 | Response to sorafenib in HCC is mediated by hypoxia-related proteins and induces distinct immune-related signatures | Jovana Hajduk | ![]() |
![]() |
|||
PH-264 | Benefits of tailored HCC surveillance programs on case-fatality rate and cancer-specific mortality using a modelling approach | Massih Ningarhari | ![]() |
![]() |
|||
PO-266 | Proteomic profiling for theranostic approches in Hepatocellular Carcinoma | Anne-Aurélie RAYMOND | ![]() |
![]() |
|||
PO-267 | Comparative in vitro evaluation of cancer therapies in various hepatocellular carcinoma experimental models | Loraine Cabral | ![]() |
![]() |
|||
PO-272 | Senescence-specific adaptive immune response to oncogene-induced-senescence (OIS) within the murine liver | Sarah Gough | ![]() |
![]() |
|||
PO-280 | Transcriptomic profiling of primary sclerosing cholangitis associated cholangiocarcinoma identifies novel genes of interest | Megan Illingworth | ![]() |
![]() |
|||
PO-284 | Predictors of survival of patients with hepatocellular carcinoma in best supportive care | Claudia Campani | ![]() |
![]() |
|||
PO-286 | Characterization of Transforming Growth Factor (TGF)-beta signalling in sorafenib-resistant hepatocarcinoma cell lines. | Ester Gonzalez-Sanchez | ![]() |
![]() |
|||
PO-287 | PD1 T-cells correlate with Nerve Fiber Density as a prognostic biomarker in patients with resected perihilar cholangiocarcinoma. | Lara Heij | ![]() |
![]() |
|||
PO-288 | Targeting of nuclear receptors and microRNA-21 ameliorates non-alcoholic fatty liver disease progression towards carcinogenesis in mice | André L. Simao | ![]() |
![]() |
|||
PH-289 | Lipid droplets are mechanical stresses in non-alcoholic fatty liver disease | Abigail Loneker | ![]() |
![]() |
|||
PO-290 | SerpinB3/4 expression is associated with poor prognosis in patients with cholangiocarcinoma | Andrea Martini | ![]() |
![]() |
|||
PH-293 | Anticancer activity of novel vicinal diaryl isoxazole compounds in hepatocellular carcinoma | Esra Nalbat | ![]() |
![]() |
|||
PH-295 | Serum IL-8 is associated with altered neutrophil phenotype and poorer survival in patients with hepatocellular carcinoma | Helen Louise Reeves | ![]() |
![]() |
|||
PO-296 | In vitro effects of magnetic hyperthermia via a nanomodified polymer stent for cholangiocarcinoma treatment | Anjali A. Roth | ![]() |
![]() |
|||
PO-300 | Genes modulating liver fat accumulation and lipogenesis predict development of hepatocellular carcinoma among direct antiviral agents treated cirrhotics C with and without viral clearance | Antonio Acquaviva | ![]() |
![]() |
|||
PO-302 | Comparison of therapeutic outcomes of liver resection and transarterial chemoembolization in multifocal HCC: a propensity score-matched analysis | Claudia Campani | ![]() |
![]() |
|||
PO-306 | Modulation of the cholangiocarcinoma stem-like compartment by monounsaturated fatty acids | Giulia Lori | ![]() |
![]() |
|||
PO-307 | Potential role of soluble triggering receptor expressed on myeloid cells 2 in risk stratification of patients with hepatocellular carcinoma | Francesca Baorda | ![]() |
![]() |
|||
BP-308 | Liver transplantation for combined hepatocellular-cholangiocarcinoma: An analysis of the European Liver Transplant Registry | Marco Claasen | ![]() |
![]() |
|||
PO-309 | Cross-talk between MerTK-expressing stromal cells and cholangiocarcinoma | Mirella Pastore | ![]() |
![]() |
|||
PO-312 | Performance of Toronto HCC risk index and aMAP score in predicting HCC development in patient with cirrhosis | Nouha Trad | ![]() |
![]() |
|||
PO-313 | Liver transplantation for fibrolamellar hepatocellular carcinoma: An analysis of the European Liver Transplant Registry | Marco Claasen | ![]() |
![]() |
|||
PO-314 | Performance of ten non-invasive liver function tests in predicting hepatocellular carcinoma development in patients with cirrhosis | Nouha Trad | ![]() |
![]() |
3-4 February 2022
![]() |
Digital Object Identifier. Official code used to identify documents published on internet; similar to ISBN for books. You may use this code to reference your poster in future scientific publications or CVs. It can be found from anywhere in the world. ![]() To find the poster page, log onto www.medra.org and enter the DOI, or enter in your internet browser https://dx.doi.org/ followed by the DOI string asigned to your congress. ![]() |
![]() |
||
![]() |
|